FDA approval and FDA clearance are different regulatory events. Approval, granted under the agency's drug authority or for the highest-risk devices, means the FDA reviewed clinical data and judged the product safe and effective for its intended use. Clearance, granted under section 510(k) of the Food, Drug, and Cosmetic Act for most moderate-risk medical devices, means the manufacturer demonstrated the device is substantially equivalent to a legally marketed predicate device — without any requirement for clinical trials. Both appear in advertising as “FDA” followed by a reassuring noun, which is precisely why the distinction matters for anyone reading a health claim. The agency itself notes that roughly half of high-risk device recalls in analyses of the 2005–2009 period traced to products that had entered through the 510(k) pathway, a statistic that frames the policy debate without settling it.
This article is information, not medical or regulatory advice. Pathways and product classifications change, and individual devices within the same pathway differ; verify any product's regulatory status in the FDA's own databases rather than in marketing copy.
The drug pathway: what approval actually requires
New drugs in the United States pass through preclinical testing, then an Investigational New Drug application, then a sequence of clinical trials — generally phases 1 through 3 — testing safety, dosing and effectiveness against controls, typically randomized and blinded. The FDA's Center for Drug Evaluation and Research reviews the full data package, and approval means the agency found the benefit-risk profile acceptable for a labeled indication, with manufacturing quality assured. Accelerated pathways — fast track, breakthrough therapy, accelerated approval — compress the timeline but do not eliminate the evidentiary core, though accelerated approvals rest on surrogate endpoints that require confirmatory trials afterward, a mechanism whose enforcement history is complicated. Post-marketing surveillance continues indefinitely, and approvals can be withdrawn.
Related stories: Cohort Study or Randomized Trial? Why the Design Behind a Finding Changes the Claim · Preprint vs Peer-Reviewed: What the Study Behind a Headline Actually Is.
The 510(k) pathway: equivalence as the standard
Class II devices — infusion pumps, surgical instruments, many diagnostic tests, joint implants among thousands of categories — generally reach the market through 510(k) clearance. The manufacturer submits a premarket notification identifying a predicate device already on the market and argues the new product is substantially equivalent in intended use and technological characteristics. No demonstration of clinical effectiveness is required in the typical case. The pathway's structural quirk is recursion: predicates were themselves often cleared against earlier predicates, so a modern device can be equivalent to a device that is equivalent to a device cleared decades ago under pre-modern evidence standards. Congress and the FDA have long debated this; the Institute of Medicine's 2011 review went so far as to recommend replacing the framework, while the agency instead created safer, more data-driven routes such as the De Novo pathway for genuinely novel moderate-risk devices.
- Approval (drugs, Class III devices): clinical effectiveness data reviewed; the claim on the label was tested.
- Clearance (most Class II devices): equivalence argued; effectiveness taken on faith from the predicate lineage.
- Registration and listing alone: some low-risk products merely register with the FDA — a fact that permits truthful-sounding phrases like “FDA-registered facility” with no product review at all.
A brief history explains how the split arose. Device regulation began in earnest with the 1976 Medical Device Amendments, which grandfathered existing devices and created the 510(k) equivalence route as a transitional courtesy. It was never designed as a permanent evidence standard for a market that now spans hundreds of thousands of products, from tongue depressors to robotic surgical systems. The risk classes map the stakes: Class I items like bandages face general controls; Class II devices face special controls and the 510(k) route; Class III devices — heart valves, implanted defibrillators, high-risk products — require the premarket approval process with clinical data. Knowing your product's class answers half of any question about how much evidence stands behind it.
Why marketing language exploits the gap
The words are engineered to blur. “FDA-cleared” appears on consumer gadgets and wellness devices whose clinical evidence is minimal; “FDA-registered” appears on supplements and cosmetics where the agency reviewed nothing about the product itself; and “FDA-approved” is sometimes used loosely for cleared devices, though the FDA has published guidance warning firms off exactly that conflation. For consumers, the translation rule is simple: approval implies the agency reviewed clinical outcome data for the labeled use; clearance implies equivalence reasoning; anything else implies less. And the FDA's device databases — publicly searchable — state which pathway each product took, in the agency's own words.
What this means for your decisions
For prescription drugs, the practical difference is small: you will almost always be taking an approved product, and the questions worth asking are about the size and quality of the trials and whether approval was accelerated. For devices, diagnostics and consumer health gadgets, ask which pathway the product took. A cleared hip implant and a cleared wellness wearable occupy the same regulatory category despite vastly different stakes — and within the cleared category, evidence quality ranges from rigorous to thin. Ask your surgeon what clinical data supports the specific implant being proposed; the question is normal, and the answer is documented in the clearance letter.
What to watch
The policy pendulum swings periodically. Legislative proposals after device-safety scandals have tightened post-market surveillance requirements and pushed 510(k) predicates toward newer baselines, while industry pressure has historically pulled the other way toward speed and flexibility. The durable consumer skill is independent of the politics: whenever a health claim leans on the letters FDA, look up which verb follows the agency's name in the product's actual regulatory record — and weight the claim accordingly.
For more context, read Surrogate Endpoints: When a Trial Measures a Stand-In Instead of the Outcome You Care About.
For more context, read relative vs absolute risk.
For more context, read observational study headlines.